Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 11/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.60 |
| ▸ | PGR | P06401 | 3/20 | 0.55 |
| ▸ | ACACB | O00763 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29564854 | 0.84 | SYK (0.59) | MTNR1BMTNR1ASMN1; SMN2ALDH1A1SYK | |
| Hydrochloric Acid SCHEMBL29564676 | 0.83 | SYK (0.58) | MTNR1BSMN1; SMN2ALDH1A1SYK | |
| SCHEMBL20567337 | 0.82 | SCN9A (0.44) | MTNR1BPGRSYKAR | |
| SCHEMBL22874617 | 0.81 | MTNR1B (0.63) | MTNR1BMTNR1APGRACACBSMN1; SMN2 | |
| SCHEMBL1980614 | 0.78 | MTNR1B (0.80) | MTNR1BMTNR1APGRALDH1A1AR | |
| SCHEMBL11637763 | 0.78 | MTNR1B (0.80) | MTNR1BMTNR1APGRALDH1A1AR | |
| SCHEMBL28528081 | 0.78 | MTNR1B (0.52) | MTNR1BMTNR1APGRSMN1; SMN2ALDH1A1 | |
| SCHEMBL4630369 | 0.76 | MTNR1B (1.00) | MTNR1BMTNR1APGRARRAF1 | |
| SCHEMBL17350083 | 0.75 | MTNR1B (0.74) | MTNR1BMTNR1APGRACACBSMN1; SMN2 | |
| SCHEMBL12672051 | 0.74 | PGR (0.54) | MTNR1BMTNR1APGRACACBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632118-B2 | Imidazolidinedione derivatives | AUTIFONY THERAPEUTICS LIMITED (GB) | 2020-04-28 | — | — | US | disclosed |
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | AUTIFONY THERAPEUTICS LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180338974-A1 | IMIDAZOLIDINEDIONE DERIVATIVES | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
| US-10632118-B2 | Imidazolidinedione derivatives | KCND3, KCNK3, KCNA3 | MTNR1B 1903/4885MTNR1A 2267/4885PGR 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.